Table 2 Immune cell density and distribution in different tumor subtypes by PD-L1 status

From: Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative

 

TNBC

HR + HER2-BC

pc

pd

PD-L1 positive (n = 13)

PD-L1 negative (n = 5)

pa

pb

PD-L1 positive (n = 9)

PD-L1 negative (n = 5)

pa

pb

Total IC density in stroma, per mm2, mean ± SD (IC composition %)

6109.4 ± 2895.3

7043.2 ± 4389.7

1.000

 

8209.6 ± 4431.9

6394.4 ± 2639.1

0.438

 

0.292

 

CD20

1020.3 ± 820.6 (16.7)

2173.7 ± 2064.4 (30.9)

0.289

<0.001

3229.7 ± 2785.9 (39.3)

1900.1 ± 1863.3 (29.7)

0.438

<0.001

0.071

<0.001

CD8

1591.6 ± 1016.9 (26.1)

1961.4 ± 1222.4 (27.8)

0.566

1215.6 ± 662.7 (14.8)

1484.5 ± 750.4 (23.2)

0.438

0.512

CD4

3497.5 ± 1236.8 (57.2)

2908.1 ± 1372.1 (41.3)

0.387

3764.3 ± 2069.9 (45.9)

3010.0 ± 538.1 (47.1)

0.438

0.794

FOXP3+ (% among CD4)

146.4 ± 67.1 (4.2)

86.3 ± 61.8 (3.0)

0.143

0.011

114.3 ± 146.9 (3.0)

83.5 ± 50.4 (2.8)

1.000

0.613

0.036

0.010

FOXP3− (% among CD4)

3351.1 ± 1214.5 (95.8)

2821.8 ± 13542 (97.0)

0.387

3650.0 ± 1960.6 (97.0)

2926.4 ± 570.1 (97.2)

1.000

0.695

Total IC density, per mm2, mean ± SD (IC composition %)

1260.5 ± 1260.5

1634.5 ± 1804.0

0.775

 

2039.1 ± 2635.9

749.7 ± 465.5

0.438

 

0.512

 

CD20

150.0 ± 187.8 (11.9)

207.7 ± 250.6 (12.7)

0.775

<0.001

955.8 ± 1371.7 (46.9)

67.0 ± 59.7 (8.9)

0.147

<0.001

0.096

<0.001

CD8

558.1 ± 634.8 (44.3)

1182.8463 ± 1331.6 (72.4)

0.566

483.2 ± 584.2 (23.7)

477.2 ± 404.7 (63.6)

0.606

1.000

CD4

552.4 ± 567.8 (43.8)

243.9 ± 294.3 (14.9)

0.208

600.2 ± 885.8 (29.4)

205.7 ± 99.3 (27.4)

0.606

0.744

FOXP3+ (% among CD4)

40.9 ± 48.8 (7.4)

10.6 ± 13.0 (4.3)

0.117

0.169

23.8 ± 30.6 (4.0)

11.1 ± 12.4 (5.4)

0.606

0.538

0.471

0.017

FOXP3− (% among CD4)

511.5 ± 528.8 (92.6)

233.3 ± 283.0 (95.7)

0.289

576.4 ± 888.9 (96.0)

194.6 ± 100.0 (94.6)

0.797

0.845

  1. TNBC triple-negative breast cancer, HR + HER2-BC hormone receptor-positive, HER2-negative breast cancer, SD standard deviation, ROI region of interest, IC immune cell, + positive, - negative.
  2. at-test, PD-L1 positive vs PD-L1 negative.
  3. bproportional test, PD-L1 positive vs PD-L1 negative.
  4. ct-test, PD-L1 positive TNBC vs PD-L1 positive HR + HER2-BC.
  5. dproportional test, PD-L1 positive TNBC vs PD-L1 positive HR + HER2-BC.
Back to article page